Schnitzler syndrome

Article written and reviewed by Dr Luca Moretti

Schnitzler syndrome is a rare acquired adult-onset autoinflammatory syndrome characterized by a distinctive clinical picture that typically includes chronic nonpruritic urticaria and monoclonal immunoglobulin M (IgM), often associated with systemic manifestations such as intermittent fever, arthralgia, bone pain, lymphadenopathy, splenomegaly and persistent inflammatory laboratory abnormalities. It is a chronic disorder belonging to the group of periodic autoinflammatory syndromes, in which dysregulation of innate immunity plays a central role, distinguishing it from classic autoimmune diseases mediated by T or B lymphocytes.

From an epidemiologic standpoint, Schnitzler syndrome is extremely rare and several hundred cases have been described; its true frequency is probably underestimated because of diagnostic delay and possible confusion with other forms of chronic urticaria or with monoclonal gammopathies. Onset is typically in adulthood.

Etiology, pathogenesis and pathophysiology

The etiology of Schnitzler syndrome remains largely unknown, but the condition is universally recognized as an acquired autoinflammatory disease rather than an inherited disorder. No specific infectious, toxic or environmental etiologic agent has been identified as a direct cause, and there is no evidence supporting familial genetic transmission. Somatic mutations described in some patients involve the hematologic clone or acquired inflammatory pathways and do not demonstrate heritability of the syndrome.

No specific risk factors for Schnitzler syndrome have been defined. The presence of an IgM or, more rarely, IgG monoclonal gammopathy is an obligate diagnostic feature, not a predisposing factor. It has been hypothesized that clonal abnormalities of B cells, particularly those involved in IgM production, may trigger the immune dysregulation underlying the syndrome. Older adult age also appears to be a predisposing context, whereas no environmental, infectious or lifestyle factors have been linked to disease onset.

The pathogenetic mechanisms of Schnitzler syndrome center on hyperactivation of the innate immune system, with particular involvement of proinflammatory cytokines, chiefly interleukin-1β (IL-1β). Immunologic studies have shown a central role for IL-1β, which accounts for many systemic clinical manifestations including fever, urticaria, osteoarticular pain and the acute-phase response. The basis of this IL-1β overproduction is not fully understood, but the monoclonal gammopathy has been hypothesized to act as a chronic stimulus of the inflammasome, causing excessive and persistent release of inflammatory cytokines.
At the molecular level, rare polymorphisms and mutations in genes involved in inflammasome regulation, such as NLRP3, have been described in some patients; however, these abnormalities are much less frequent than in inherited autoinflammatory syndromes and are not a defining feature of Schnitzler syndrome.

From a pathophysiologic standpoint, chronic activation of innate immunity induces a persistent systemic inflammatory response, with increased acute-phase proteins such as CRP, ESR and SAA, neutrophilic leukocytosis and increased serum ferritin. The monoclonal IgM component, usually present at low levels (<3 g/dL), reflects clonal B-cell proliferation, which in rare cases may progress to more aggressive lymphoid disorders such as Waldenstrom macroglobulinemia or lymphoma. Organ damage results mainly from uncontrolled chronic inflammation and activation of endothelial cells and involved tissue structures, producing the systemic and local manifestations characteristic of the disease.

Clinical manifestations

Schnitzler syndrome has a polymorphic, multisystem clinical presentation whose complexity often makes early recognition difficult. The cardinal manifestation, present in virtually all patients, is chronic nonpruritic urticaria, characterized by transient erythematous papular lesions with a truncal and proximal distribution that rarely involve the palms or soles.
These skin lesions typically appear daily or almost daily, last several hours and resolve without scarring or pigmentation. The clinical appearance differs from classic urticaria because pruritus is absent or mild and because the lesions are resistant to conventional antihistamine treatment. Histologic examination shows a predominantly neutrophilic dermal infiltrate, often without frank vasculitis, reflecting the autoinflammatory nature of the disorder.

Another almost constant symptom is intermittent fever, generally low to moderate grade, recurring over time and often associated with marked malaise, chills and profuse sweating. The febrile episodes are pathophysiologically related to persistent activation of proinflammatory cytokines, particularly IL-1β, which acts on the hypothalamic thermoregulatory center and raises body temperature.

Common systemic manifestations include arthralgia and myalgia, preferentially affecting large joints such as the knees, hips and shoulders, and sometimes associated with morning stiffness. Some patients develop true arthritis with swelling, erythema and joint pain. The migratory and nonerosive nature of these manifestations suggests predominantly inflammatory rather than adaptive immune-mediated involvement.

Particularly suggestive diagnostically is deep bone pain, often localized to the long bones, pelvis and ribs. This symptom, present in about half of cases, reflects inflammatory activation of bone and marrow, with possible increased bone turnover and, in more advanced cases, cortical thickening and hyperostosis visible on imaging.

Lymphadenopathy, meaning enlargement of peripheral lymph nodes, and splenomegaly are less frequent findings but indicate systemic involvement, attributable to expansion of lymphoid tissue and persistent immune activation. Hepatomegaly may also occasionally be found.

The clinical course is chronically relapsing and may persist for many years, often with progressive worsening of systemic manifestations in the absence of targeted therapy. In rare cases, the syndrome may progress to more serious hematologic disorders such as Waldenstrom macroglobulinemia or non-Hodgkin lymphoma.

Investigations and diagnosis

The diagnosis of Schnitzler syndrome is clinically challenging because of the rarity of the disorder and the frequent overlap of symptoms with other hematologic, rheumatologic or dermatologic conditions. The diagnostic pathway follows a rational sequence beginning with clinical suspicion, continuing with laboratory and instrumental assessment and culminating in application of specific diagnostic criteria, always supported by exclusion of alternative disorders.

Clinical suspicion generally arises in an adult with chronic nonpruritic urticaria accompanied by intermittent fever and systemic symptoms such as arthralgia, myalgia and bone pain. These symptoms tend to persist despite conventional treatments and are associated with laboratory abnormalities indicating chronic inflammation, prompting a more detailed assessment.

Routine blood tests typically show marked elevation of inflammatory markers such as ESR, CRP and SAA, accompanied by neutrophilic leukocytosis, normocytic anemia and sometimes thrombocytosis.
Increased serum ferritin and beta-2 microglobulin are also often found, reflecting persistent systemic inflammatory activation.
A crucial step in the diagnostic work-up is serum protein electrophoresis with immunofixation, which identifies a monoclonal component, usually IgM but sometimes IgG, virtually always present in affected patients and generally below 3 g/dL. Periodic monitoring of the monoclonal component is also important because of the rare risk of progression to more aggressive hematologic disorders.

Among further investigations, skin biopsy of the urticarial lesions is particularly relevant: histopathology typically shows a predominantly neutrophilic perivascular dermal infiltrate without evidence of leukocytoclastic vasculitis, a feature that helps distinguish the syndrome from other dermatologic conditions with similar manifestations.
In patients with persistent bone pain, radiography of the long bones, bone scintigraphy or magnetic resonance imaging may demonstrate cortical thickening, hyperostosis or evidence of marrow activation, whereas abdominal ultrasound and CT are useful to assess lymphadenopathy and splenomegaly. Bone marrow evaluation is indicated according to the characteristics of the monoclonal component, cytopenias, lymphadenopathy or other findings raising suspicion of a hematologic neoplasm; it is not restricted to suspected transformation.

A crucial aspect of the diagnostic pathway is careful exclusion of other conditions capable of mimicking the clinical and laboratory picture of Schnitzler syndrome. These include chronic idiopathic urticaria, cryoglobulinemia, inherited autoinflammatory syndromes, monoclonal gammopathies of undetermined significance, systemic vasculitides, connective tissue diseases, chronic infections and lymphoid neoplasms.

Diagnosis is based on the Strasbourg criteria, developed by international experts from the earlier Lipsker criteria. These are not EULAR guidelines.

The Strasbourg criteria include:

• obligate criteria: chronic urticarial rash and monoclonal IgM or IgG gammopathy;
• minor criteria: recurrent fever, abnormal bone remodeling with or without bone pain, a neutrophilic dermal infiltrate on biopsy, and neutrophilic leukocytosis or elevated CRP;
• for a definite diagnosis with IgM, both obligate criteria and at least two minor criteria are required; with IgG, at least three minor criteria are required;
• for a probable diagnosis with IgM, at least one minor criterion is sufficient; with IgG, at least two minor criteria are required.

Early diagnosis of Schnitzler syndrome is important because it allows severe complications to be avoided and specific therapy to be started promptly, significantly improving quality of life and modifying the natural course of the disease.

Treatment and prognosis

Management of Schnitzler syndrome has evolved substantially in recent years because of growing understanding of its pathogenetic mechanisms and the introduction of targeted therapies. Management aims at rapid and sustained control of cutaneous and systemic manifestations and normalization of inflammation; it has not been demonstrated that IL-1 inhibitors reduce the risk of hematologic transformation.

Until the last decade, treatment was based mainly on symptomatic approaches, which were often unsatisfactory. Second-generation antihistamines are generally ineffective, as are systemic corticosteroids, which may provide only transient relief and carry significant adverse effects with prolonged use. Conventional therapies for chronic urticaria, including immunosuppressants such as methotrexate, cyclosporine or dapsone, have shown efficacy in only a minority of cases and do not alter the course of the disease.

The major therapeutic advance has been the use of interleukin-1 inhibitors, which have transformed the prognosis of Schnitzler syndrome. The most widely used and validated agent is anakinra, an IL-1 receptor antagonist administered subcutaneously. In nearly all patients, anakinra produces rapid and complete remission of both cutaneous and systemic manifestations, with normalization of inflammatory markers and substantial improvement in quality of life. In clinical practice, treatment interruption almost always leads to symptom recurrence, making continuous administration necessary in most cases. Other anti-IL-1 agents, such as canakinumab, a monoclonal anti-IL-1β antibody, and rilonacept, an IL-1 decoy receptor, have proved effective in selected cases, although their availability is more limited and their use is generally reserved for disease refractory to or intolerant of anakinra.

In patients with contraindications to or an inadequate response to anti-IL-1 therapy, other immunomodulatory approaches have been tried, including IL-6 inhibitors such as tocilizumab, anti-TNF agents and rituximab, with variable results generally inferior to those of IL-1 blockade. The role of plasma exchange, chemotherapy or intensive immunosuppressive therapy is limited to exceptional cases with progression to lymphoid disease.

Regular monitoring is essential both to assess the clinical response and to detect possible progression of the monoclonal gammopathy to a hematologic neoplasm, although this remains uncommon. Periodic follow-up with blood tests, serum protein electrophoresis and multidisciplinary clinical assessment is recommended.

From a prognostic standpoint, Schnitzler syndrome was historically considered a chronic and severely disabling disease with a significant risk of inflammatory complications and neoplastic transformation. Today, anti-IL-1 therapy has markedly improved symptom control, inflammatory markers and quality of life. However, without specific treatment the disease tends to persist and worsen over time, with a risk of organ damage secondary to chronic inflammation and possible progression to hematologic malignancies such as Waldenstrom macroglobulinemia or non-Hodgkin lymphoma.

Complications

The complications of Schnitzler syndrome arise mainly from the chronic systemic nature of uncontrolled inflammation and from the presence of the monoclonal gammopathy. Without adequate therapy, persistent inflammation may lead to progressive multiorgan involvement and structural and functional damage in target tissues.

Among the most frequent and feared complications is progression to hematologic malignancies. The persistent presence of a monoclonal IgM component, or more rarely IgG, carries a limited but real risk of progression to Waldenstrom macroglobulinemia, non-Hodgkin lymphoma or, much more rarely, other lymphoproliferative neoplasms. Long-term hematologic surveillance is indicated, but no syndrome-specific cytogenetic factors have been validated to predict transformation.

Chronic activation of the innate immune system and persistent inflammatory cytokine production also expose patients to systemic complications. AA amyloidosis may occur, especially when longstanding inflammation remains uncontrolled, because of amyloid deposition in tissues, with resulting renal, cardiac or gastrointestinal dysfunction. Hyperostosis and bone remodeling are characteristic manifestations and may sustain chronic pain; pathologic fractures are not an established typical complication of the syndrome.

Chronic renal failure is mainly a consequence of AA amyloidosis in cases of persistent uncontrolled inflammation. Other organ involvement has been described in isolated cases but does not represent a well-established typical complication of the syndrome.

Finally, the symptomatic burden of the syndrome, especially when inadequately treated, substantially impairs quality of life, with chronic fatigue, persistent pain, functional limitation and an increased risk of opportunistic infections in patients treated long term with immunosuppressants or corticosteroids.

References
1. Lipsker D et al. The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore). 80, 1, 2001, 37-44.
2. de Koning HD. Schnitzler's syndrome: lessons from 281 cases. Clinical and Translational Allergy. 4, 2014, 41.
3. Simon A et al. Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy. 68, 5, 2013, 562-568.
4. Braud A, Lipsker D. Schnitzler Syndrome: Insights into Its Pathogenesis, Clinical Manifestations, and Current Management. Biomolecules. 14, 6, 2024, 646.
5. Krause K et al. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study. Journal of Allergy and Clinical Immunology. 139, 4, 2017, 1311-1320.
6. Sokumbi O et al. Clinical and histopathologic review of Schnitzler syndrome: The Mayo Clinic experience (1972-2011). Journal of the American Academy of Dermatology. 67, 6, 2012, 1289-1295.
7. Niederhauser BD et al. Imaging findings in 22 cases of Schnitzler syndrome: characteristic para-articular osteosclerosis, and the hot knees sign differential diagnosis. Skeletal Radiology. 43, 7, 2014, 905-915.
8. de Koning HD et al. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Annals of the Rheumatic Diseases. 72, 10, 2013, 1634-1638.
9. Jain T et al. Schnitzler syndrome: an under-diagnosed clinical entity. Haematologica. 98, 10, 2013, 1581-1585.
10. de Koning HD et al. Schnitzler Syndrome: Beyond the Case Reports: Review and Follow-Up of 94 Patients with an Emphasis on Prognosis and Treatment. Seminars in Arthritis and Rheumatism. 37, 3, 2007, 137-148.